Generated: May 22, 2017
|Title:||Inhibitors of human phosphatidylinositol 3-kinase delta|
|Abstract:||Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K.delta.) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3K.delta. plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3K.delta., while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3K.delta. activity, including compounds that selectively inhibit PI3K.delta. activity. Methods of using PI3K.delta. inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3K.delta. inhibitory compounds to inhibit PI3K.delta.-mediated processes in vitro and in vivo.|
|Inventor(s):||Sadhu; Chanchal (Bothell, WA), Dick; Ken (Bothell, WA), Treiberg; Jennifer (Bothell, WA), Sowell; C. Gregory (Mukilteo, WA), Kesicki; Edward A. (Bothell, WA), Oliver; Amy (Bothell, WA)|
|Assignee:||ICOS Corporation (Indianapolis, IN)|
|Filing Date:||Oct 07, 2009|
|Claims:||1. A compound of formula IV ##STR00093## wherein Y is null; R.sup.10 is selected from the group consisting of H, halo, OH, OCH.sub.3, CH.sub.3, and CF.sub.3; R.sup.11 is selected from the group consisting of H, OCH.sub.3, and halo; R.sup.12 is selected from the group consisting of phenyl, halophenyl, and alkylphenyl; R.sup.d, independently, is selected from the group consisting of NH.sub.2, NH(C.sub.1-3alkyl), N(C.sub.1-3alkyl).sub.2, and C.sub.1-3alkyl; and q is 1 or 2; or a pharmaceutically acceptable salt thereof; provided that: (a) at least one of R.sup.10 and R.sup.11 is different from 6-halo or 6,7-dimethoxy groups; and (b) R.sup.12 is different from 4-chlorophenyl. |
2. The compound of claim 1, wherein R.sup.12 is alkylphenyl, or a pharmaceutically acceptable salt thereof.
3. The compound of claim 2, wherein R.sup.10 is CH.sub.3 and R.sup.11 is H, or a pharmaceutically acceptable salt thereof.
4. The compound of claim 3, wherein R.sup.d is NH.sub.2, or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1, wherein the compound is 2-(6-aminopurin-9-ylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one, or a pharmaceutically acceptable salt thereof.
6. A pharmaceutical composition comprising an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
7. A pharmaceutical composition comprising an effective amount of a compound of 2-(6-aminopurin-9-ylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.